Frontier IP has announced that portfolio company The Vaccine Group (“TVG” or the “Company”) has appointed Dr Jeremy Salt as Chief Executive Officer.
Jeremy has extensive experience in senior roles in animal healthcare across organisations in the commercial and not-for-profit sectors. He is joining TVG from GALVmed, a not-for-profit organisation that develops and makes available livestock vaccines, medicines and diagnostics for small-scale livestock producers, where he was Chief Scientific Officer. GALVmed is funded by the UK government’s Foreign, Commonwealth & Development Office through UKAID and the Bill & Melinda Gates Foundation.
Before GALVmed, he was the director of Biologicals Research & Development for the Europe, Africa and Middle East arm of the world’s biggest animal health group Zoetis, and previously the vaccines division of Pfizer Animal Health. Jeremy has completed a PhD in the immunology of foot and mouth virus persistence.
As TVG Chief Executive, Jeremy will be responsible for the continued development and commercialisation of the Company’s novel vaccine platform technology, which is being used to develop a wide range of different vaccines to combat zoonotic and economically-damaging diseases. These include vaccines to combat COVID-19, Ebola, Lassa fever, African Swine Fever, porcine respiratory and reproductive virus (PRRSV), and bovine tuberculosis.
The University of Plymouth spin out and its international partners have so far been awarded more than £9 million in grants from the UK, US and Chinese governments. It has also signed its first commercial deal with ECO Animal Health Group plc and The Pirbright Institute to develop vaccine candidates to combat PRRSV, one of the most economically damaging diseases to the pig industry. Frontier IP holds a 17 per cent equity stake in TVG.
I am delighted to be taking this leadership role with The Vaccine Group at this important time in its development. The COVID-19 pandemic has raised the profile of vaccines as a key component of infectious disease control. The importance of multiple technological approaches to vaccine development has been shown to be critical. The Vaccine Group is well-positioned to contribute to this market with its novel vaccine platform technologies.
Jeremy Salt, Chief Executive Officer of The Vaccine Group
Jeremy’s experience in animal healthcare, including vaccines, across several major organisations will be invaluable to The Vaccine Group as it evolves its technology, brings it to market and develops into a successful company. We are working to strengthen management teams across our portfolio, and we are very pleased Jeremy has decided to join TVG. We very much look forward to working with him to make the Company the success it deserves to be.
Frontier IP Chief Executive Officer Neil Crabb
